[Ballardin M, Gemignani F, Bodei L, Mariani G, Ferdeghini M, Rossi AM, Migliore L, Barale R. (2002). Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res514(1-2): 77-85.]Search in Google Scholar
[de Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiere E, Meunier F, Parmentier C, Hill C, Sancho-Garnier H. (1997). Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 75(5): 734-739.]Search in Google Scholar
[Edmonds CJ, Smith T. (1986). The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59(697): 45-51.]Search in Google Scholar
[Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, Haghpanah V. (2011). Incidence of second primary malignancies during a longterm surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med 36(4): 277-282.]Search in Google Scholar
[Fenech M. (2000). The in vitro micronucleus technique. Mutat Res 455(1-2): 81-95.]Search in Google Scholar
[Grudeva-Popova J, Yaneva M, Zisov K, Ananoshtev N. (2007). Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. J BUON 12(1): 129-132.]Search in Google Scholar
[Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. (1997). Micronuclei induction by 131I exposure: study in hyperthyroidism patients. Mutat Res373(1): 39-45.]Search in Google Scholar
[Hosseinimehr SJ. (2010). Flavonoids and genomic instability induced by ionizing radiation. Drug Discov Today 15(21-22): 907-918.]Search in Google Scholar
[Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117(19): 4439-4446.]Search in Google Scholar
[Kolade VO, Bosinski TJ, Ruffy EL. (2005). Acute promyelocytic leukemia after iodine-131 therapy for Graves’ disease. Pharmacotherapy 25(7): 1017-1020.]Search in Google Scholar
[Little JB. (2000). Radiation carcinogenesis. Carcinogenesis 21(3): 397-404.]Search in Google Scholar
[Monteiro Gil O, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, Leonard A, Gerber G, Rueff J. (2000). Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis15(1): 69-75.]Search in Google Scholar
[Robbins RJ, Schlumberger MJ. (2005). The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46 Suppl 1: 28S-37S.]Search in Google Scholar
[Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP. (2009). Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19(5): 451-457.]Search in Google Scholar
[Schroeder T, Kuendgen A, Kayser S, Kroger N, Braulke F, Platzbecker U, Klarner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U. (2012). Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica97(2): 206-212.]Search in Google Scholar
[Watanabe N, Kanegane H, Kinuya S, Shuke N, Yokoyama K, Kato H, Tomizawa G, Shimizu M, Funada H, Seto H. (2004). The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J NuclMed 45(4): 608-611.]Search in Google Scholar
